Maraviroc for HIV/AIDS

"This medical trial seeks to enroll participants aged 2-18 years old. Altogether, there are 150 trials involving minors and 471 targeting adults beyond the age of 65."

"Presently, 5 active studies for Maraviroc are taking place in 27 cities and 12 countries. The first of these trials began in 2009 under the sponsorship of ViiV Healthcare; this phase 2 study recruited 103 participants before it was completed. Since then, another 99 such undertakings have been launched."

"To qualify for this trial, participants must suffer from acquired immunodeficiency syndrome and be between the age of 2 and 18. To fulfil the requirements of this study, 103 patients are required to take part in it."

"This clinical trial is not presently taking on any new patients. This study was initially published in April 2009 and underwent its most recent update in April of 2020. If you are seeking other trials, there are currently 636 studies actively recruiting participants with acquired immunodeficiency syndrome and 5 studies for Maraviroc that require participants."

"This clinical trial will primarily evaluate the Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events (AEs) at Weeks 2 and 48 post-dose. Secondary objectives include assessing the Change From Baseline in Percentage (%) of CD4+ Cells between Weeks 24 and 48, Number of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) or Protease Inhibitor (PI) Resistance Associated Mutations (RAMs), as well as Percentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration from Baseline to Week 24/48."

"As of right now, 18 clinical sites are taking on participants for this trial. Locations span from Jacksonville to Atlanta and Wilmington as well as other places in the United States. It is recommended that patients choose a location near them in order to reduce their need for travel if they take part in the study."

"Taking into account the fact that this trial is at Phase 2, our analysts have concluded that Maraviroc can be considered moderately safe and assigned it a score of 2."

"Maraviroc was initially explored in 2009 at IRCCS Ospedale Pediatrico Bambino Gesu, with 99 studies having been completed since then. Currently there are 5 ongoing trials occurring mainly out of Jacksonville, Florida."

"Unfortunately, clinicaltrials.gov reveals that recruitment for this particular medical trial has concluded as of April 17th 2020 - the last time it was updated. Although no longer active, 641 other studies are actively recruiting patients at this moment in time."